Paragon Bioservices named to Baltimore Business Journal's "Fast 50"
December 18, 2017
This article was first published by PRNewswire.
BALTIMORE, Dec. 18, 2017 /PRNewswire/ -- Paragon Bioservices, a global leader in the manufacturing of biopharmaceuticals and vaccines, is proud to be a recipient of BBJ's Fast 50 Award this year.
On November 29th, the Baltimore Business Journal hosted the award ceremony for this year's list at the Center Club in Baltimore, MD for the fastest growing private companies in the greater Baltimore region. This year's annual list was ranked by percent change in revenue from 2015-2016.
"It is very exciting to be named to the list for the first time. Baltimore is a great place to be in the biotech business. Being on this list demonstrates the outstanding work of our entire team," said Paragon's CEO Pete Buzy. "We offer our clients a unique experience by tailoring each project towards their specific needs. Paragon provides end-to-end drug development capabilities, specializing in the scale-up and manufacturing of novel vaccines and cutting edge gene therapy medicines for industry leading biotechnology companies."
About Paragon Bioservices, Inc.
Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon's aim is to build strong client partnerships with the world's best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.